-+ 0.00%
-+ 0.00%
-+ 0.00%

Press Release: AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen(R) Toward Planned Phase 3 Development in Pancreatic Cancer

Dow Jones·08/10/2026 12:36:00

Please log in to view news